{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:38:38Z","timestamp":1791855518419,"version":"4.3.4"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Dermatol"],"published-print":{"date-parts":[[2016]]},"DOI":"10.4103\/0019-5154.174087","type":"journal-article","created":{"date-parts":[[2016,1,28]],"date-time":"2016-01-28T07:19:11Z","timestamp":1453965551000},"page":"119","source":"Crossref","is-referenced-by-count":6,"title":["Use of topical rapamycin in facial angiofibromas in Indian skin type"],"prefix":"10.4103","volume":"61","author":[{"given":"Parul","family":"Thakur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishalakshi","family":"Viswanath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poonam","family":"Pund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0019-5154.174087-1","first-page":"888","volume-title":"Facial Angiofibroma Severity Index (FASI): Reliability assessment of a new tool developed to measure severity and responsiveness to therapy in tuberous sclerosis-associated facial angiofibroma","author":"Salido-Vallejo","year":"2014","journal-title":"Clin Exp Dermatol"},{"key":"key-10.4103\/0019-5154.174087-2","first-page":"624","volume-title":"Tuberous sclerosis complex consensus conference: Revised clinical diagnostic criteria","author":"Roach","year":"1998","journal-title":"J Child Neurol"},{"key":"key-10.4103\/0019-5154.174087-3","first-page":"657","volume-title":"Absence of signs of systemic involvement in four patients with bilateral multiple facial angiofibromas","author":"Hunter","year":"2010","journal-title":"Am J Med Genet A"},{"key":"key-10.4103\/0019-5154.174087-4","first-page":"713","volume-title":"Facial angiofibromas of tuberous sclerosis: Successful treatment with podophyllin","author":"T\u00fcrkmen","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key-10.4103\/0019-5154.174087-5","first-page":"140","volume-title":"Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis","author":"Bissler","year":"2008","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0019-5154.174087-6","first-page":"54","volume-title":"Topical rapamycin (sirolimus) for facial angiofibromas","author":"Madke","year":"2013","journal-title":"Indian Dermatol Online J","ISSN":"https:\/\/id.crossref.org\/issn\/2229-5178","issn-type":"print"},{"key":"key-10.4103\/0019-5154.174087-7","doi-asserted-by":"crossref","unstructured":"Truchuelo T, D\u00edaz-Ley B, R\u00edos L, Alc\u00e1ntara J, Ja\u00e9n P. Facial angiofibromas treated with topical rapamycin: An excellent choice with fast response. Dermatol Online J 2012;18:15.","DOI":"10.5070\/D36TB7N61M"},{"key":"key-10.4103\/0019-5154.174087-8","first-page":"473","volume-title":"The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis","author":"Hofbauer","year":"2008","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/0019-5154.174087-9","first-page":"3677","volume-title":"Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex","author":"Tarasewicz","year":"2009","journal-title":"Transplant Proc"},{"key":"key-10.4103\/0019-5154.174087-10","doi-asserted-by":"crossref","unstructured":"Haemel AK, O\u2032Brian AL, Teng JM. Topical rapamycin: A novel approach to facial angiofibromas in tuberous sclerosis. Arch Dermatol 2010;146:715-8.","DOI":"10.1001\/archdermatol.2010.125"},{"key":"key-10.4103\/0019-5154.174087-11","first-page":"138","volume-title":"A novel application of topical rapamycin formulation, an inhibitor of mTOR, for patients with hypomelanotic macules in tuberous sclerosis complex","author":"Wataya-Kaneda","year":"2012","journal-title":"Arch Dermatol"},{"key":"key-10.4103\/0019-5154.174087-12","first-page":"63","volume-title":"Topical rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: Follow up of a pilot study and promising future directions","author":"Tu","year":"2014","journal-title":"Australas J Dermatol"},{"key":"key-10.4103\/0019-5154.174087-13","first-page":"14","volume-title":"Analysis of current data on the use of topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis complex","author":"Balestri","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key-10.4103\/0019-5154.174087-14","first-page":"165","volume-title":"Facial angiofibromas of tuberous sclerosis treated with topical sirolimus in an Indian patient","author":"Vasani","year":"2015","journal-title":"Indian J Dermatol","ISSN":"https:\/\/id.crossref.org\/issn\/0019-5154","issn-type":"print"},{"key":"key-10.4103\/0019-5154.174087-15","first-page":"121","volume-title":"Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: A double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin","author":"Koenig","year":"2012","journal-title":"Drugs R D"}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:31:39Z","timestamp":1786649499000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/0019-5154.174087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016]]}},"alternative-id":["174087"],"URL":"https:\/\/doi.org\/10.4103\/0019-5154.174087","relation":{},"ISSN":["0019-5154"],"issn-type":[{"value":"0019-5154","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]}}}